3.Giugliano RP, Pedersen TR, Saver JL, et al. Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis [published...
FH familial hypercholesterolaemia, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, Lp(a) lipoprotein (a), PCSK9i protein convertase subtilisin/kexin type 9 inhibitor Full size image 3.4 Safety Analysis
Effect of the PCSK9 inhibitor evolocumab on total cardiovascular events in patients with cardiovascular disease: a prespecified analysis from the FOURIER trial. JAMA Cardiol. 2019;4(7):613–9. Article PubMed PubMed Central Google Scholar Cordero A, Rodríguez-Mañero M, Fácila L, Fernández-...
[30]Sabatine MS,LeiterLA,WiviottSD,etal.Cardiovas- cularsafetyandefficacyofthePCSK9inhibitorevo- locumabinpatientswithandwithoutdiabetesandthe effectofevolocumabonglycaemiaandriskofnew- onsetdiabetes:aprespecifiedanalysisofthe FOU- RIERrandomisedcontrolledtrial[J].LancetDiabetes Endocrinol,2017,5(12):941-...
Fig. 1. Preference groups based on patient characteristics per type of PCSK9 inhibitor according to healthcare professionals. In patients who initiated PCSK9 mAbs before the availability of PCSK9 siRNA, 32 % of healthcare professionals would consider offering a switch to PCSK9 siRNA. Additionally,...
(LDL)-cholesterol <70 mg/dL, with the recommendation that ezetimibe or a PCSK9 inhibitor be added to maximum tolerated statins for LDL cholesterol ≥70... Z Bloomgarden - 《Journal of Diabetes》 被引量: 0发表: 2023年 SMARTPHONE APPLICATION TO RISK STRATIFY PATIENTS WITH CORONARY ARTERY DISEASE...
including the use of epidermal growth factor-A mimetics to block PCSK9 binding of the LDL-R (13) and inhibitors of pro-PCSK9 autoprocessing and/or secretion (14); unfortunately, the PCSK9-LDL-R complex has a relatively flat surface that makes binding by a small molecule inhibitor challengin...
“These data reinforce our confidence that MK-0616 could become the first oral PCSK9 inhibitor, with the potential to change the way patients with hypercholesterolemia who need additional LDL-C reduction are treated. This may allow many more patients ...
In summary, the COMBO studies are the longest duration placebo/ezetimibe-controlled trials of a PCSK9 inhibitor in high-risk patients with poorly controlled LDL-C on maximum tolerated standard of care. They will help to guide clinical decision making on the next LLT to use beyond statin therapy...
In summary, the COMBO studies are the longest duration placebo/ezetimibe-controlled trials of a PCSK9 inhibitor in high-risk patients with poorly controlled LDL-C on maximum tolerated standard of care. They will help to guide clinical decision making on the next LLT to use beyond statin therapy...